Comparative safety of JAK inhibitors versus TNF or IL-17 inhibitors for cardiovascular disease and cancer in psoriatic arthritis and axial spondyloarthritis
These results are reassuring that among a large population of people with PsA or axSpA, JAKi was not associated with increased risk of CVD or common solid cancers, compared to TNFi or IL-17i initiators. Ongoing monitoring of cardiovascular and cancer risks is needed.
Authors
- David R. J. Riley (ORCID: https://orcid.org/0000-0002-0905-6524)
- Gema Hernandez
- Uazman Alam (ORCID: https://orcid.org/0000-0002-3190-1122)
- Sizheng Steven Zhao (ORCID: https://orcid.org/0000-0002-3558-7353)
Institutions
- University of Liverpool (GB)
- Aintree University Hospitals NHS Foundation Trust (GB)
- Manchester University NHS Foundation Trust (GB)
- TriNetX (United States) (US)
Publication Details
- Journal
- Clinical Therapeutics
- Published
- 2025-02-05
- DOI
- https://doi.org/10.1016/j.clinthera.2025.01.005
- Citations
- 11
- Primary Topic
- Spondyloarthritis Studies and Treatments
- Type
- article
- Field-Weighted Citation Impact
- 18.35
Funders
- National Institute for Health and Care Research
- Psoriasis and Psoriatic Arthritis Alliance
- Versus Arthritis
- Manchester Biomedical Research Centre